About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

Sponsored by

Translational Lung Cancer Research is sponsored by General Hospital of Eastern Theater Command, Nanjing, China

Sponsored by

Original Article

Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation
Yishan Yu, Linlin Wang, Shufen Cao, Siming Gao, Weili Wang, Lianne Mulvihill, Mitchell Machtay, Pingfu Fu, Jinming Yu, Feng-Ming (Spring) Kong
Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease
Yuanjun Liu, Yaoyao Zhu, Ran Wu, Min Hu, Lingnan Zhang, Qingren Lin, Denghu Weng, Xiaojiang Sun, Yu Liu, Yaping Xu
Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2
Sha Huang, Tianyu He, Sijia Yang, Hongxu Sheng, Xiuwen Tang, Feichao Bao, Yiqing Wang, Xu Lin, Wenfeng Yu, Fei Cheng, Wang Lv, Jian Hu
Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma
Yutao Liu, Yu Feng, Ting Hou, Analyn Lizaso, Feng Xu, Puyuan Xing, Hongyu Wang, Qiaolin Kang, Lu Zhang, Yuankai Shi, Xingsheng Hu
Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy
Yanjun Xu, Hui Li, Zhiyu Huang, Kaiyan Chen, Xiaoqing Yu, Jiamin Sheng, Han-Han Zhang, Yun Fan
The feasibility of navigation bronchoscopy-guided pulmonary microcoil localization of small pulmonary nodules prior to thoracoscopic surgery
Junxiang Chen, Xufeng Pan, Chuanjia Gu, Xiaoxuan Zheng, Haibin Yuan, Jun Yang, Jiayuan Sun
Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
Xiangwei Ge, Zhibo Zhang, Sujie Zhang, Fang Yuan, Fan Zhang, Xiang Yan, Xiao Han, Junxun Ma, Lijie Wang, Haitao Tao, Xiaoyan Li, Xiaoyu Zhi, Zhiyue Huang, Paul Hofman, Arsela Prelaj, Giuseppe Luigi Banna, Luciano Mutti, Yi Hu, Jinliang Wang
Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study
Ziqing Zeng, Bo Yan, Yulong Chen, Lianmin Zhang, Jianquan Zhu, Fan Yang, Feng Wei, Terence Chi Chun Tam, Diego Kauffmann-Guerrero, Ross Andrew Soo, Xiubao Ren, Jian You
Hsa_circ_0006571 promotes spinal metastasis through sponging microRNA-138 to regulate sirtuin 1 expression in lung adenocarcinoma
Hou-Lei Wang, Hui-Ren Wang, Yun Liang, An-Nan Hu, Francisco J. Enguita, Xiao-Gang Zhou, Jian Dong
Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)
Tongji Xie, Yan Li, Jianming Ying, Weijing Cai, Junling Li, Kye Young Lee, Biagio Ricciuti, Jose Pacheco, Puyuan Xing
The protective effects of granulocyte-macrophage colony-stimulating factor against radiation-induced lung injury
Dan Hu, Yan Zhang, Ruiqi Cao, Yuying Hao, Xiaoye Yang, Tiantian Tian, Jiandong Zhang

Editorial on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions1

Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?
Francesco Passiglia, Silvia Novello

Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions1

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
Bing Xia, Misako Nagasaka, Viola W. Zhu, Sai-Hong Ignatius Ou, Ross A. Soo
How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?
Simon Ekman
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
Fabrizio Tabbò, Maria Lucia Reale, Paolo Bironzo, Giorgio V. Scagliotti
The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
Ibiayi Dagogo-Jack, Lauren L. Ritterhouse
Decade in review: a new era for RET-rearranged lung cancers
Noura J. Choudhury, Alexander Drilon
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
Alessandro Russo, Andrés F. Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
Janna Josephus Anna Oda Schoenmaekers, Marthe Sentijna Paats, Anne-Marie Clasina Dingemans, Lizza Elisabeth Lucia Hendriks
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
Kenichi Suda, Tetsuya Mitsudomi
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Francesca Bersani, Deborah Morena, Francesca Picca, Alessandro Morotti, Fabrizio Tabbò, Paolo Bironzo, Luisella Righi, Riccardo Taulli
Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas
Matthias S. Matter, Obinna Chijioke, Spasenija Savic, Lukas Bubendorf
Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review
Ana Ortega-Franco, Virginia Calvo, Fabio Franco, Mariano Provencio, Raffaele Califano
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
Gianmarco Leone, Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Silvia Novello
How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease
Lorenza Landi, Federico Cappuzzo

Consensus

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
Wenhua Liang, Kaican Cai, Chun Chen, Haiquan Chen, Qixun Chen, Junke Fu, Jian Hu, Tao Jiang, Wenjie Jiao, Shuben Li, Changhong Liu, Deruo Liu, Wei Liu, Yang Liu, Haitao Ma, Xiaojie Pan, Guibin Qiao, Hui Tian, Li Wei, Yi Zhang, Song Zhao, Xiaojing Zhao, Chengzhi Zhou, Yuming Zhu, Ran Zhong, Feng Li, Rafael Rosell, Mariano Provencio, Erminia Massarelli, Mara B. Antonoff, Toyoaki Hida, Marc de Perrot, Steven H. Lin, Massimo Di Maio, Antonio Rossi, Dirk De Ruysscher, Robert A. Ramirez, Wolfram C. M. Dempke, D. Ross Camidge, Nicolas Guibert, Raffaele Califano, Qi Wang, Shengxiang Ren, Caicun Zhou, Jianxing He

Disclosure:

1. The series “Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Silvia Novello and Francesco Passiglia served as the unpaid Guest Editors for the series.

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
Bryan A. Chan, Brett G.M. Hughes
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
Global trends of lung cancer mortality and smoking prevalence
Farhad Islami, Lindsey A. Torre, Ahmedin Jemal
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao
Tackling ALK in non-small cell lung cancer: the role of novel inhibitors
Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello
Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?
Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Jeryl Villadolid, Asim Amin

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis
Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song
BRAF mutations in non-small cell lung cancer
Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper
The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer
Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper
Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice
Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song
Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song
Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer
Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen
The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants
Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden
The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices
Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement
Hyojin Kim, Jin-Haeng Chung
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer
Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao
Clinical trials for lung cancer in China
Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu
Recurrence after surgery in patients with NSCLC
Hidetaka Uramoto, Fumihiro Tanaka
Prognostic markers in lung cancer: is it ready for prime time?
Chang-Qi Zhu, Ming-Sound Tsao
Potential biomarkers for lung cancer screening
Gabriella Sozzi, Mattia Boeri
Particle therapy in non-small cell lung cancer
Zhongxing Liao, Charles B. Simone II
Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions
Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai
Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer
Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft
Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors
Suchit H. Patel, Andreas Rimner, Roger B. Cohen
Intraoperative near-infrared imaging of mesothelioma
Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal
BAP1, a tumor suppressor gene driving malignant mesothelioma
Mitchell Cheung, Joseph R. Testa
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation
Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update
Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang
Immunotherapy for malignant pleural mesothelioma: current status and future directions
Jordan Dozier, Hua Zheng, Prasad S. Adusumilli
Biology and clinical significance of circulating tumor cell subpopulations in lung cancer
Linda O’Flaherty, Harriet Wikman, Klaus Pantel
Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?
Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace
Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer
Sumitra Mohan, Francesca Chemi, Ged Brady
Biophysical technologies for understanding circulating tumor cell biology and metastasis
Derrick W. Su, Jorge Nieva
Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer
Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno
Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer
Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis
Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

Editorials

Dulanermin in cancer therapy: Still much to do
Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data
Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner
Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung
Pedro Mendez, Jose Luis Ramirez
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr
Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review
Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack
Lorenza Landi, Federico Cappuzzo

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung
Yoon Jin Cha, Hyo Sup Shim
Immunohistochemistry for predictive biomarkers in non-small cell lung cancer
Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Original Article

Comprehensive genomic profiling of combined small cell lung cancer
Jing Zhang, Liping Zhang, Jie Luo, Tao Ge, Pengyu Fan, Liangdong Sun, Likun Hou, Junqiang Li, Huansha Yu, Chunxiao Wu, Yuming Zhu, Chunyan Wu, Gening Jiang, Giancarlo Troncone, Jyoti Malhotra, Katsuhiro Okuda, Mariacarmela Santarpia, Rita Zamarchi, Taichiro Goto, Andrés F. Cardona, Jianfang Xu, Qiankun Chen, Zhonghong Zhang, Peng Zhang, written on behalf of the AME Lung Cancer Collaborative Group

Review Article


Review Article